## NBIX: Neurocrine Biosciences, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 1.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($146.06)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 0, Bearish: 0)

**1. Neurocrine Biosciences, Inc. $NBIX Shares Sold by Brown Advisory Inc.**
- Source: MarketBeat | 20251207T042204 | Somewhat-Bullish | Relevance: 99%
-  Brown Advisory Inc. reduced its stake in Neurocrine Biosciences (NASDAQ:NBIX) by 33.1% in Q2 2025, selling 296,323 shares but still retaining a significant holding. Despite this sale, other major institutional investors like Dodge & Cox and JPMorgan Chase & Co. increased their positions, leading to institutional ownership of approximately 92.59%. Neurocrine Biosciences reported strong Q3 earnings, exceeding analyst expectations, and has received multiple "Buy" ratings and upward revised price targets from analysts, with a consensus target of $172.00.

**2. Hood River Capital Management LLC Sells 79,626 Shares of Neurocrine Biosciences, Inc. $NBIX**
- Source: MarketBeat | 20251208T120950 | Neutral | Relevance: 98%
-  Hood River Capital Management LLC reduced its stake in Neurocrine Biosciences, Inc. by 23.6% in the second quarter, selling 79,626 shares and now owning 257,538 shares valued at $32.37 million. Company insiders also sold 33,300 shares worth $4.93 million, decreasing their ownership to 4.30%. Neurocrine Biosciences exceeded Q3 earnings and revenue estimates, prompting analysts to maintain a "Moderate Buy" rating with a target price of $172.

**3. Arrowstreet Capital Limited Partnership Acquires 58,562 Shares of Neurocrine Biosciences, Inc. $NBIX**
- Source: MarketBeat | 20251209T080950 | Neutral | Relevance: 98%
- Arrowstreet Capital Limited Partnership increased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 87.9% in the second quarter, now owning 125,162 shares worth $15.73 million. Other institutional investors also adjusted their positions, and company insiders have sold shares totaling over $4.9 million in the last three months. Neurocrine Biosciences reported strong Q3 earnings, beating analyst estimates, and analysts have set new price targets, with a consensus "Moderate Buy" rating.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | RBC Capital | $180 | $160 | +12% |
| 2025-12-05 | TD Cowen | $200 | $175 | +14% |
| 2025-11-11 | Morgan Stanley | $173 | $178 | -3% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | RBC Capital | main | Outperform |
| 2025-12-05 | TD Cowen | main | Buy |
| 2025-11-11 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($0.72M) |
| Sells | 5 ($2.33M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 53.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Blackrock Inc.: 12.7% (-1.9%)
- Vanguard Group Inc: 9.7% (-1.0%)
- JPMORGAN CHASE & CO: 9.5% (+122.0%)
- Dodge & Cox Inc.: 5.6% (-0.2%)
- State Street Corpora: 4.4% (-2.7%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.27 indicates undervaluation relative to growth. Forward P/E 16.9x attractive for 33% earnings growth. Quality metrics strong (margin 16%). Balance sheet: strong liquidity (3.4x), low leverage (D/E 0.42). Analyst sentiment positive (2 raises, avg +13%). Insider selling cluster ($2.3M in 90 days), potential headwind. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $15.5B |
| Beta | 0.27 |
| 52W Range | $84.23 - $160.18 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.27 |
| Forward P/E | 16.9 |
| Current P/E | 22.5 |
| YoY Growth | 32.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 weakening modestly (-0.6% over 5 days). Below STRENGTH zone by 1.9pp (needs >3.0% for momentum thesis). MRS_5 at 0.2% confirms short-term momentum alignment. Outperforming sector by 5.6pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (0.94), confirming momentum.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 1.06% (CS: 69) | Neutral |
| RSI_14 | 64.3 | Neutral |
| MACD Histogram | 0.94 | Bullish |
| vs SMA20 | 1.052x | Above |
| vs SMA50 | 1.076x | Above |
| vs SMA200 | 1.208x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $155.02
- **Stop Loss:** $146.06 (5.8% risk)
- **Target:** $163.98 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 33
- **Position Value:** $5,115.66
- **Portfolio %:** 5.12%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-02-05 (Est: $2.41)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.07 | $2.17 | +4.9% |
| 2025Q2 | $1.50 | $1.65 | +9.6% |
| 2025Q1 | $1.09 | $0.70 | -36.0% |
| 2024Q4 | $1.93 | $1.69 | -12.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*